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DR. ROBERT S. CHAPMAN: (U.S. EPA): I will
confine myself to some comments and questions
on the three talks we have heard this morning,
all of which I think were very interesting and
informative. I want to start out by saying I have
nomajor areas ofdisagreementwiththe interpre-
tations that the speakers have given us today.
With regard to Dr. Ferris' presentation, begin-
ning with his discussion of children's lung func-
tion in Steubenville, I interpreted Dr. Ferris as
sayingthatthecorrelation betweenpollutant lev-
els and residual FEV1 values was higher when
there was no real pollution alert than when an
actual alert occurred. In my mind, this observa-
tion may reflect temporal variation in the sub-
jects' experience with respiratory infection.
Within a specific location, respiratory infection
hasbeen showntovary substantially fromyearto
year, with respect both to incidence and to infec-
tious agents. It seems to me that infection is an
important covariant in a study such as this, since
it produces changes in lung function. I do not
think thatthe Steubenville results willbe conclu-
sive until respiratory infection has been more
thoroughly assessed. It seems to me that a hy-
pothesis that deals with respiratory infection is
more tenable than one that deals with fatigue on
the part of either subjects or the testing team,
since testing took place at one-week intervals
during the testingperiods in Steubenville.
I would be interested to hear Dr. Ferris' com-
ments on this idea. I am glad to hear that the
investigators plan to continue observing lung
function in Steubenville. I hope that some esti-
mate of community experience with respiratory
infectionmightbedeveloped insubsequent obser-
vations, and perhaps retrospectively, too, for
those that have already been made.
Thrning now to Dr. Ferris' comments on re-
spiratory illness before age two in relation to
living inhomeswithgas stoves, myreadingofthe
various analyses shown by Dr. Ferris this morn-
ing is that they are qualitatively consistent with
each other, particularly if the last two analyses,
which reflect the introduction ofnew cohorts, are
not considered. This consistency among analyses
is more striking to me than the differences that
Dr. Ferris stressed. How confident can we be that
children before age two lived in the same kind of
home, with respect to cooking fuel, as they lived
in at the time of survey? Might it be that the
proportion of children whose families had
changed cooking fuel differed from analysis to
analysis? Ifso, is it possible that such differences
influenced the results of the various analyses
performed?
Regarding Dr. Bates' review of available evi-
dence, I would say that the Office of Air Quality
Planning and Standards was aware, prior to the
standard-setting process, of the Kurata study
that Dr. Bates mentioned. An evaluation was
prepared ofthat study for OAQPS, which came to
very much the same conclusion as Dr. Bates did
this morning. I find the Southern Ontario Hospi-
tal admission study extremely interesting. I have
only been acquainted with it for 12 hours and
therefore do not feel I can make a particularly
detailed assessment ofit. It certainly is interest-
ing that such significant correlations were ob-
served in view ofthe low ozone levels measured.
Like Dr. Bates, I tend to favor the hypothesis
that Ontario residents may be less tolerant to
ozone exposure than Southern Californians. Ex-
perimental work in Southern California has
shown larger changes in Canadians' lung func-
tion than in Southern Californians' lungfunction
in response to the same ozone concentration.
There is, however, one analytic design feature of
Dr. Bates' study that may present a source of
possible bias. This arises from my understanding
that the analyses were specific for day of week,
but were not specific for season ofyear. The small
amount ofdatawe have seen so far would suggest
that ozone levels were higher in summer than in
winter, at least in 1978. It would seem to me,
therefore, that Dr. Bates' analytic design might
promote an artifactual association between ozone
exposure and respiratory diagnoses whose intrin-
sic properties would favor summer occurrence.
Just as importantly, this design might obscure a
true association between ozone exposure and res-
piratory conditions which most frequently occur
inwinter. Such conditionswouldinclude illnesses
with an important infectious component, andDISCUSSION: SESSION V
would thus include the first six of this study's
nine diagnoses. Therefore, we wouldbe considera-
bly more confident of the results presented if a
season-specific analysis were performed in addi-
tion to the analysis specific for day ofweek.
llrning to Dr. Kuller's interesting talk, I be-
lieve that the HANES II type ofcarboxyhemoglo-
bin analysis is certainly interesting in providing
preliminary leads. However, I have reservations
about the feasibility of measuring carboxyhemo-
globin in a continuing population study. Impor-
tant questions arise in my mind as to how many
people's carboxyhemoglobin should be measured,
and how often each person's carboxyhemoglobin
should and can be assessed. I would be interested
in hearing Dr. Kuller's remarks on these ques-
tions. With regard to his estimate of 1250 excess
deaths attributable to carbon monoxide exposure,
I certainly can't come up with a more specific
estimate. However, I do wonder, as Dr. Kuller
indeed mentioned, whether such a number of
deaths, presumably scattered across the United
States, would be detectable by epidemiologic tools
currently available. Indeed, it seems to me that
any effect that ambient CO might be expected to
exert on cardiovascular or reproductive parame-
ters would probably be very subtle in relation to
the effects ofother factors. Thus I think it advisa-
ble to perform careful feasibility studies in these
areas prior to launching full-scale field studies,
which would of necessity be very expensive.
There would appear to be two major questions to
address in feasibility studies. First, in view of
existing information, would an effect ofthe pollu-
tant be expected to occur? If so, would scientific
tools at hand be capable oftesting for it?
It seems to me that for CO, and perhaps for
other pollutants, it might be well for the govern-
ment and other funding sources to support more
such formal feasibility evaluations prior to fund-
ing full-scale studies, so that both investigators
and sponsors would have a fairly clear idea at the
outset whether meaningful tests can be devel-
oped. It might also be useful from a methodologic
standpoint to publish feasibility study results
more frequently in scientificjournals. I hasten to
add I would not bias this assessment in terms of
probability of finding an effect, only in terms of
whether a meaningful test could be performed.
I would be most interested to hear Dr. Kuller's
views, if any, on impedence cardiography as a
potentially noninvasive and field-applicable way
ofmeasuring systolic time intervals (STIs). First,
would accurate, noninvasive measurements of
STIs be useful in community studies of carbon
monoxide exposure, and if so, how bright are the
prospects for developing technology for this use?
The reason I askthis isthat impedence cardiogra-
phy is currently being used in experimental CO
studies in North Carolina, and I would appreciate
more information as to whether energetic pursuit
ofthis technology would be a good idea.
I would like to close by commending the Har-
vard six-cities study investigators for what I
think is a lively appreciation of the appropriate
tempo at which epidemiologic studies can proceed
and at which epidemiologic results should be pub-
lished. I think one of the underlying lessons of
this symposium has been that it is absolutely
fruitless to rush into print with results that the
investigators have not contemplated very care-
fully. It seems to me that the six-city investiga-
tors are doingjustthatpriorto publishinghealth-
related results, and I think they are to be
commended for it. I hope that investigators and
sponsors alike will take a lesson from them.
DR. D. V. BATES: (St. Pauls Hospital, Vancou-
ver): I didn'tmake the point clear in my presenta-
tion, thus I am not surprised Dr. Chapman didn't
get it. The only days which met the criteria for
the optimum level were days in summertime. So
the relationship to ozone is entirely a seasonal
relationship. None of the winter days met that
criterion, but I didn't make that clear and I think
that is important.
I would like to say something about the infec-
tive component. I should also have pointed out
that none ofmy marker conditions, cerebral hem-
orrhage, renal infection or anything else showed
any relationship to the pollutants. So they were
all negative. But in relation to infection, there is
a great deal of further analysis needed here,
because the animal data, which I didn't have time
to talk about, tells us that ozone at concentrations
of as low as 0.1 ppm interferes with the defenses
against bacterial infection in miners, for in-
stance, by interfering with macrophage function.
So there is every reason to suggest that when this
analysis is carried a step further, one should look
at whether the infective categories which I have
included are indeed ones which are showing some
increase, or whether it is primarily the asthmatic
categories. We are at the beginning ofan exhaus-
tive analysis of these data, which will take us
some time, and there is every reason from the
animal data to look at the relationship of infec-
tious diseases to oxidants and probably the other
pollutants as well. I don't think a bias in the
study was introduced by not confining it to differ-
ent seasons but it is easy to separate the effects of
season.
DR. L. H. KULLER: (Univ. ofPittsburgh): Firstof
142DISCUSSION: SESSION V
all, the big debate about monitoring CO is
whether you monitor the ambient air using CO
samplers in the community, or monitor carboxy-
hemoglobin. It is my feeling that it is rather silly
to put monitors around places where traffic is, or
locations where cars idle, measure the CO and
find levels very high, and say that acommunity is
in or out of compliance. I don't think it tells us
very much except that a lot of cars go by the
sampler, and occasionally traffic is slow. It seems
to me that blood-drawing in the population is
frequently done. There are large numbers ofpeo-
ple who contribute blood to blood banks. I don't
reallythinkthe discrepancy between the Milwau-
kee and HANES results is a function ofsampling,
but isrelated tothe abilityto measure carboxyhe-
moglobin accurately.
I think there is an opportunity to use blood
from blood donors or other sources available, and
monitor carboxyhemoglobin in a community, as
well as in high risk populations, that is, to check
industrial and other sources as well. Or one can
use expired air carbon monoxide from alveolar
samples. Sources of CO are related to the home
environment, occupation, smoking, and from air
pollution, and it is unreliable to have a few air
pollution monitors around town and try to esti-
mate the exposure of the population for carbon
monoxide by this means. We are always talking
about the need for a personal monitor. Here we
have a personal monitor and basically we don't
use it.
As far as the question about the systolic time
intervals and impedence cardiography, I am not
an expert in this area, but I will say something
about it. Ifthese techniques are to be used, they
first have to be evaluated. Do they measure any-
thing inrelationship to outcome, do they measure
an increased risk of heart attacks or survival
outcomes, or something like that? As far as I
know, none ofthese methods has really been put
to this test. Second, are they repeatable? Most of
the time these tests are not very repeatable.
Third, do we have any data from population prev-
alence or from other studies, to compare these
criteria with others? The answer to that is gener-
ally no.
We can do plain electrocardiography, exercise
testing, radionucleotide testing with exercise,
count the number ofhospitalizations, count heart
attacks, look at coronary angiograms, look at
postmortem materials; these are all well defined
end points. Our problem is not measuring heart
disease, our problem isrelating heart disease and
risk of events to carboxyhemoglobin. I suggest
that we emphasize the design of studies and not
add new measurements which are unnecessary. I
am reminded ofpulmonary function testing prob-
lems, where a whole variety ofways ofmeasuring
pulmonary function were developed, but they
have not been linked to specific disease processes.
DR. DOROTHY MCCRAW: (Shell Oil): I under-
stand there is a dispute on the size of inhalable
particles. Is that the case? Ifnot, what is the size
of inhalable particles? Question two is to Dr.
Bates and perhaps Dr. Chapman. Are you famil-
iarwiththeHouston area oxidant studies and can
you comment?
DR. B. G. FERRIS (Harvard School of Public
Health): With respect to inhalable particles, one
must ask: Inhalable to where in the respiratory
tract? The dichotomous sampler collects particles
under 15 gm, but some of the ones bigger than
that can impinge on the nose, and you may have
reactions there. I call attention to the ethmoid
and nasal sinus cancers reported inwoodworkers,
in whom the larger wood particles perhaps de-
posit in the nasal area. But the smaller the parti-
cle, the more likely it is to be deposited more
deeply in the lung. This is our reason for looking
at the dichotomous sample of particles between
15 to 2.5 gm and smaller. I think the important
thing ifyou are talkingaboutparticles isthatyou
define the particle sizes. Later on we will be able
to sort outprecisely where they are going to go in
the pulmonary tissues.
DR. BATES: I havejust been a week in Houston
andGalveston. Mydifficultywithyourquestion is
that all ofthe data that I have seen from Houston
have been privileged. I am not really able to
discuss it except in the context ofprivileged infor-
mation. I haven't seen anything in open scientific
publications yet which one can discuss in this
symposium. I hope that this work will be pub-
lished soon.
DR. EDWARD P. RADFORD (Univ. ofPittsburgh):
On the question of measuring blood carboxyhe-
moglobin in community studies, I agree with Dr.
Kuller that this is a personal monitor which is
unique in the air pollution field. On the other
hand, it is not an easy problem. We have had to
work very hard to get the quality control we
needed in order to get the data he showed. My
conclusion has been there has been no significant
trend over time in ambient carbon monoxide. In
fact, I question some of those emission data Dr.
Kuller showed because I don't think they really
standupto critical inspection. Thecatalytic after-
burner didn't really come in until the late 1970s,
and yet a very sharp downward trend from trans-
portation sources was shown considerably before
that.
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I have a question on the oxidant issue. Dr.
Bates notably did not say anything about the
chromosomal aberration studies that have been
done both in animals and in man. I would like to
ask him whether he thinks this is a significant
end point that has not been looked at adequately.
DR. BATES: I mentioned I was going to include
in my talk only epidemiological studies. I think
that is a very good question because exposure of
people to ozone at existing levels undoubtedly
doesproduce evidence ofincreasedbreaks in chro-
mosomes, similar to the data that were shown
yesterday in relation to low exposures to benzene.
I have taken the trouble to ask a lot ofpeople in
this field what significance we should attach to
that observation. What I came out with-and it is
certainly subject to change-is that those results
in general are not interpretable in terms of any
long-term consequences. I am not an expert in
that field and I really don't know whether this is
the right answer, but it is the answer that you
seem to get at this point in time from those in the
cytogenetic field not involved with standard set-
ting.
DR. Y. ALARIE (Univ. of Pittsburgh): I would
like to introduce something for the panelists to
look at. As we consider these standards, somehow
they should be related in one way or another to
their toxicity. Dr. Bates mentioned that ozone is
indeed a very toxic gas, and what I have listed in
Table 1 are the values for sulfur dioxide and
nitrogen dioxide for annual arithmetic mean air
quality standard aspublished inApril 1971 in the
Federal Register for those two gases.
Now ifI look at the standard for these materi-
als, they don't seem to make much sense to me.
On an annual arithmetic mean we would have a
standard for nitrogen dioxide at 100 ig/M3 or 0.05
ppm which is higher than for sulfur dioxide. Tox-
icologically it makes no sense. For ozone, we have
a 1-hr arithmetic meanbut we do not have such a
standard on a 1-hr basis for SO2 or NO2. We do
have a 24-hr arithmetic mean for SO2, which I
have listed as 0.14 ppm to 0.12 ppm for 1 hr of
ozone. I don't think that makes much sense
either. IfI consider the toxicological rating that I
amgivingthose gases, andprobably othertoxicol-
ogists may notpick exactly the same number that
I have given, but they would certainly be in the
same order that I have chosen.
Thus it appears to me with that for the stan-
dard for SO2 we have a large margin of safety
Table 1. National ambient air quality standards.
Averaging Primary Secondary
Pollutant time standardsab standards
S02 Annual 80 gg/M3
arithmetic mean (0.03 ppm)
24 hr 365 jig/M3
(0.14 ppm)
3 hr 1300 jg/M3
(0.5 ppm)
Total suspended Annual 75 jg/M3 60 jg/M3
particulate (TSP) geometric mean
24 hr 260 jg/M3 150 jg/M3
Lead Quarterly 1.5 jig/m3c Same as primary
average standard
CO 8 hr 10 mg/m3 Same as primary
(9 ppm) standard
1 hr 40 mg/m3
(35 ppm)
03 1 hr 235 jg/m3d Same asprimary
(0.12 ppm) standard
Total 3 hr 160 jg/m3e Same as primary
nonmethane (0.24 ppm) standard
hydrocarbons
Nitrogen Annual 100 jig/M3 Same asprimary
dioxide arithmetic mean (0.05 ppm) standard
aEnvironmental Protection Agency, Federal Register 36 (84): 8197 (April 30, 1971).
bNational standards other than ozone and those based on annual arithmetic means or annual geometric means are not to be
exceeded more than once per year. The ozone standard is written so that the average nunmber ofdays per year above the standard
must be less than or equal to one.
cEnvironmental Protection Agency, Federal Register 43 (194): 46246-46277 (October 5, 1978).
dEnvironmental Protection Agency, Federal Register 44 (28): 8202-8237 (February 8, 1979).
eA planning standard used to develop ozone control strategies.
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with that standard at 0.03 ppm. On the other
hand, with the ozone standard at 0.12 ppm, we
are dangerously close to levels at which we can
detect effects, certainly toxicological effects ofim-
portance. We can detect toxicological effects with
ozone in animals in the 0.2-0.4 ppm range rather
easily, both acute effects on 1 hr of exposure as
well as chronic effects. Certainly there is no way
we can do that in animals with sulfur dioxide at
0.03 ppm. No study has been able to detect any-
thing in rats or guinea pigs exposed 24 hr/day for
their lifetime, andforupto 2 yrwith monkeys. At
thatlevel there isnotoxicologically demonstrable
effect.
Somehow these standards are being put to-
gether by different groups. The groups who look
at SO2 and ozone are writing their reports and
making recommendations independently. Some-
how things are not meshing, at least from a
toxicological rating of these chemicals. I would
likethe viewofthe panel onhowwe can approach
things in a better way, if we are looking at not
only one standard by itselfbut also how it relates
to other chemicals for which we have a standard,
when the protection we are trying to get is fairly
closely the same for these chemicals.
DR. BATES: I wouldjust like to respond in rela-
tion to ozone, because I think the scientific com-
munity has made it abundantly clear that they
share Dr. Alarie's views. There is no safety factor
whatever in the standard of 0.12 ppm. All I can
say is that different committees are involved in
different standard-setting processes. The social,
economic and societal factors that led to the re-
cent upward change in the ozone standard are no
doubt defensible, but they were not based, as far
as I am concerned, on any consideration of com-
parative toxicology.
DR. CHAPMAN: Idon't disagree withwhat either
Dr. Alarie or Dr. Bates has said. However, it does
seem to me that the comparison presented in
Table 1 is somewhat arbitrary in nature due to
the broad difference in averaging times that the
various standards reflect. The ozone standard, for
example, is a 1-hr standard. Ifone multiplies the
0.14 ppm 24-hr standard for SO2 by 24, one ob-
tains aroughestimate ofa 1-hrSO2 leveltowhich
this standard would correspond. I think that such
an estimate would be more appropriate to
present. Also, such an estimate is more consistent
with Dr. Alarie's relative toxicology ratings than
the figures he has shown.
Also, I think the standard-setting process re-
flects to some extent the fact that environmental
epidemiology, and air pollution epidemiology in
particular, is still in its infancy. I think it impor-
tant to note that the search for long-term effects
ofphotochemical oxidant exposure has hardly yet
begun.
DR. ALARIE: It doesn't matter that the stan-
dards are on a different basis, as I pointed out.
There is no problem at all, toxicologically, to
demonstrate an effect for short periods of time
with ozone. So therefore, we have no safety mar-
gin built into the ozone standard, none whatso-
ever. Now if you take the 24-hr or annual stan-
dard for sulfur oxide, I don't care which one you
pick, there is a good safety margin in them. In
essence we can project the ozone standard to an
annual average. Ifwe do this, the annual average
would be below levels that we can really control.
DR. CHAPMAN: Dr. Bates' studies would seem to
confirm what you are saying with respect to
ozone.
DR. KULLER: Ithinkthere is anotherfactor, and
that is what we might call the attributable risk.
You can look at toxicological properties as you
have done, but I think one also has to look at the
total health status of the population, and how
much one would attribute to each of these air
pollution factors to evaluate their control. In
terms of standards, this is a very critical ques-
tion. I don't think we are going to be able to
control all environmental or social factors in dis-
ease to a level that would eventually eliminate
disease orreduce itto the pointwe might like. We
havetodecide onhowmuchdisease inthepopula-
tion can be attributed to these pollutants at their
current levels, andhence whatdegree ofcontrol is
required. In terms of human health, ozone is
much moretoxicthanSO2. Howmuchozone is the
population willing to accept to prevent potential
health effects?
DR. ALARIE: There is absolutely no question
that ozone is a lot nastier than sulfur dioxide.
DR. KULLER: But is it nastier than cigarette
smoking?
DR. ALARIE: We are comparing air quality stan-
dards for pollutants, and I think if you want to
start comparing them to cigarette smoke, I give
up.
DR. BATES: I tried to make it clear that there
were some interesting features about photo-
chemical oxidants. Because ozone reactswithNO,
ifyou stand in a downtown city region you actu-
ally get less ozone under these conditions than
you do out inthe country. Ifyou analyze our data,
the air pollution stations showing the highest
ozone are those in rural regions. Ifyou want to be
protected, you should stand at an intersection
where a lot ofNO is being produced, because the
03 reacts and hence is diminished.
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The answer to the cigarette argument is that
people breathing ambient air pollutants have no
choice. That fact radically alters the situation. I
believe, as studies are replicated, the cost-benefit
argument will come home to roost with a ven-
geance. I suspect within a few months of our
paper being published, economists will tell On-
tario how much pollution is costing them every
year in dollars. If you want to confine the argu-
ment to economics, you can cost out each hospital
admission, with an average of 9 days stay. For
every hospital admission there are probably two
or three emergency admissions. We have other
data suggesting for each of those there are five
visits to a family physician, and increased medi-
cation costs. The moment that you get into this
argument, I suspectthatthe insistence on quanti-
tating benefits in terms of dollars will really
become unpopular. At that point, the politicians
will abandon cost-benefit arguments. Cynically,
what you will see is that as soon as you get
reliable data to say what the costs really are from
these pollutants, you will find the whole argu-
ment is abandoned in favor of next week's fash-
ionable basis for comparison.
DR. CHAPMAN: I would like to add, with respect
to that urban street corner, we should not forget
that we would be exposed to considerable levels of
NO2 in the situation Dr. Bates described.
DR. BATES: Yes. You swap pollutants. Ofcourse,
there would be more CO as well.
DR. ALARIE: One final point that I would like to
make onphotochemical oxidant, andIwouldhave
done exactly as Dr. Bates did, ifyou ask scientists
to talk on photochemical oxidant they generally
talk about ozone. That is just one component of
the mix of photochemical oxidants, and yet I
think inthe near future we mayhave some rather
unpleasant surprises as we change over from gas-
oline engines to diesel engines. For the photo-
chemical oxidant one starts with a series ofshort-
chain hydrocarbons, either saturated or
unsaturated. It is the unsaturated ones which
react with NO and NO2, under the action of sun-
light. They produce, among other things, perox-
yacylnitrates.
The product depends on which kind of unsatu-
rated hydrocarbon you start with. You start with
butadiene, propylene or acetylene and you often
end up with other types of products, such as
acrolein, formaldehyde, or others. If, on the other
hand, you start with short-chain aromatic compo-
nents like styrene, nitro-olefins or peroxyarylni-
trates are formed, and these are a lot more potent
as irritants, including pulmonary irritants. The
new gaseous and particulate phase exhaust prod-
ucts, when irradiated by sunlight, may give us
some rather surprising results. That is really
what I call photochemical oxidant smog. It is not
ozone; it is a mixture of very potent chemicals
about which we know very little. This mixture is
really what the population is being exposed to.
Right now we are using ozone as a surrogate,
because we can measure ozone more easily than
we can measure the hundred or so other chemi-
cals beingformed, plus all ofthe free radicals that
are being formed during this period oftime. As a
result we may adopt some control strategy for a
pollutant but perhaps gain very little benefit. By
indicating these single pollutants, as we have
been blaming sulfur dioxide and now we are go-
ingto blame ozone, or are blaming carbon monox-
ide as the agent in cigarette smoke which pro-
vokes cardiac attacks, I am not sure that we are
really going in the right direction.
DR. RADFORD: Specifically referring to ozone,
which at least may be one of the perhaps more
serious constituents ofphotochemical smog, I find
it very interesting that the 8-hr time-weighted
average occupational exposure limit is now less
than the 1-hr limit for the general population,
which is very surprising. In other words, we are
protecting workers more than the general public
in this case.
With regard to the carbon monoxide issue, one
of the points that I think did not come through
very clearly is that, as identified in the HANES
study, the population being exposed significantly
to carbon monoxide, other than from cigarette
smoking, is that exposed largely to indoor
sources-occupational exposures in the case of
the adults. Exposure is not from ambient air. The
HANES study, unfortunately did not include
some ofthe cities like Denver andAlbuquerque at
high altitude, but did include Los Angeles, down-
townManhattan, the Bronx, Pittsburgh, Chicago,
Atlanta, Minneapolis, etc. We found the only sig-
nificant elevations that could be ascribed to out-
door CO sources were in downtown Manhattan
and Los Angeles. I think that Denver would also
qualify as another area with significant outdoor
exposures. Nevertheless CO is far from being a
widespread problem from outdoor sources in the
United States.
This issue is related to the point just made:
where has our target been? We can identify car-
bon monoxide as a bad thing to have around, but
where is it coming from? Ifit turns out not to be
from sources where we are putting all ofoureffort
in protecting the public, then we may be wasting
our resources.
DR. ALARIE: I couldn't agree more. Inthe case of
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carbon monoxide control we are wasting money.
There is absolutely no question about that.
DR.MAURICESHAPIRO(Univ. ofPittsburgh): We
owe a debt of thanks to Dr. Ferris and his co-
workers for undertaking an important scientific
study andfordevoting somuchefforttogathering
information which otherwise would have been
nearly impossible to obtain. But I do have a
question concerning FEV1 measurements. Is
there any relationship between FEV1 measure-
ments and temperature? Secondly, in Dr. Ferris'
study were questions asked of individuals about
their subjective concerns with the conditions of
the ambient air just before measurements were
taken?
DR. BATES: There are a lot ofdata on repetitive
FEV-1 values in normal subjects, showing varia-
tions by time ofday. There are not much data on
seasonal variation, such as might relate to tem-
perature, and it is incomplete. I don'tbelieve that
his study included a questionnaire administered
immediately before the FEV1 was measured, cer-
tainly not in the case ofthe children.
The problem of variability of results is, as he
pointed out, severe. He can show differences in
mean but he was careful to point out they did not
attain statistical significance. All ofthese expira-
tory flow measurements have considerable intra-
individual variability and of course even more
between individuals, which makes interpreta-
tions complex. I think the research team has
taken extraordinary precautions against those
kinds of errors, and particularly against instru-
ment error. You may have seen a recent paper on
granite workers in Vermont; their FEV1 values
were all wrong because the instrument went
wrong between repetitive tests. I think they have
really taken careful account to avoid that kind of
difficulty. We are getting sequential measure-
ments from the six-city study of a much higher
quality ofsequential measurements thanwe have
ever had before.
What I think the study is showing-and I am a
keen supporter ofit-is the difficulty ofknowing
what question to ask, and the dependence ofthe
answer to some extent on the way you take ac-
count ofdifferent variables. I think that issue is
going to prove a very important lesson for epide-
miological studies in general.
DR. CHAPMAN: One other comment is that
though some studies appear to show a seasonal
effect on spirometric measurements, the Harvard
investigators are confining themselves to five or
six week periods. This would tend to minimize
such an effect, since they are staying within-
season for each separate analysis.
DR. BATES: Some years ago I published a paper
in which we studied the FEV1 and MMFR in 216
chronic bronchitics in four different cities in Can-
ada every month of the calendar year. We could
find no variation between winter and summer in
those measurements. That is, there was no sea-
sonal difference in FEV1 and MMFR in 216 men
with chronic bronchitis. There are other data of
that kind in the literature. But the sort of data
Dr. Ferris is collecting in children and normal
people, with regard to seasonal variation and so
on. I think is highly original andthere isn't much
to compare it with.
DR. KULLER: I want to make a comment about
what Dr. Shapiro said a moment ago. It is a
problem for epidemiologists in all studies, that is,
the interraction between the person's participa-
tion and the outcome variable that you are mea-
suring. I think Dr. Ferris has attempted very
carefully to control for that problem. Other stud-
ies clearly have not and have wound up with
somewhat spurious results. In many ofthe mea-
surements we do, not only ofpulmonary function
but in any measurement which involves the par-
ticipant's effort, we get into similar difficulties.
The same thing occurs with the exercise testing
and some ofthe work on carbon monoxide.
With regard to the CO problem, not only do we
have to lookwhere the CO is comingfrom, but we
also have to remember we are dealing with a
small population athigh risk, atleastifwe accept
the work from Aronow and others, and I think
that is the critical group. The real problem is: Is
that population being exposed, where are they
being exposed, and what are the sources of CO?
As far as I know, nobody has really focused on
that particular problem.
I would like to point out that my estimate of
1200 deaths in nonsmokers with heart disease
possibly related to a moderate increase ofcarbon
monoxide from whatever source is an astounding
numberofevents inthe UnitedStatespopulation.
Itmaybe small compared to the number ofpeople
who die of heart disease, but it is large in rela-
tionship to some of the other agents we have
talked about in the past few days. Not to deni-
grate any of those agents, but we are talking
about health effects in the population and public
health implications, and 1200 deaths, if that is
thenumber, is anextraordinarily largenumberof
events. So onthe one hand, CO is a small problem
for most ofus. On the other hand, considering the
disease it operates on, cardiovasculardisease, and
the fact that we can really show health effects, it
couldbeby farone ofthe mostimportant environ-
mental pollutants that we deal with.
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I think Dr. Alarie agreed with this last point. I
was not saying that ozone wasn't important, but
in modifying technology in relationship to con-
trolling pollutants we seem to create other prob-
lems which we didn't expect. Since I have had a
diesel car it seems as ifmy vegetation at home is
disintegrating and turning brown, and I am won-
dering whether diesel exhaust is destroying the
vegetation on my property. It is reducing my fuel
costs but it may be destroying the vegetation.
MR. JACOB GLATTER (Rockville, MD): I would
like to address a question to Dr. Chapman. At the
end ofhis review he statedthe need for feasibility
studies, rather than jumping in with both feet
relative to epidemiologic field studies on CO.
Without going through the excellent and articu-
late presentation by Dr. Kuller concerning CO
and how it affects high riskpopulations (although
they are small), the empirical evidence acquired
to date points to CO as a potential environmental
hazard. Isn't the problem basically that ofdesign-
ingaprotocol that isrigorous, takinginto account
the clinical and experimental evidence available,
subjecting that protocol to peer review, and then
getting on with good epidemiological studies?
DR. CHAPMAN: I hope that will turn out to be
the problem. However, I think that any effect of
ambient CO on cardiovascular or reproductive
parameters would be subtle in relation to the
effects ofotherfactors, and might be very difficult
to test for with available scientific methods. This
consideration, coupled with the expense ofa field
study, leads me to believe that feasibility studies
in these areas would be useful in sharpening
subsequent research efforts. It is my feeling that
feasibility studies arejust as likely to expand the
reasonable purview of future research as to con-
tract it. Of course, there is room for honest dis-
agreement on this topic.
DR. BATES: Can I put in a heretical disclaimer?
Having taught many graduate students and done
a lot of research myself I always say that the
graduate student who is obsessive about method-
ology never does anything at all. You have to be
very careful in trying to balance ahighly original
approach to an old problem with the kind of
exacting and perhaps more pedestrian approach
being suggested here.
Let me cite an example. I planned the Ontario
studytwoyears ago with Dr. Ferris. We wereboth
sure it would show nothing. We did it because my
expectation is the ozone levels will continue to go
up, and I wanted a baseline to compare what is
going to happen in 1980, 1981 or 1982. We did it
for a total cost of $15,000, because the hospital
data were available to me on tape and the air
pollution data were published.
It was intended as a baseline study, but we
were both astonished when it came out with a
positive result. Thus, when someone has an idea
to do a study, even ifit is not in final form and all
aspects completely anticipated, it is important
not to determine the probable outcome on some
theoretical basis. I think that is an important
concept, particularly in relation to graduate stu-
dent teaching. In other words, the idea that one
should have a go at a study, even with an incom-
plete protocol, is well worth urging on people.
Thus I give a slightly heretical and different view
to the overplanned, overdesigned, and allegedly
highly meticulous study which sometimes turns
out to be far less interesting than more prelimi-
nary data from a less structured study.
DR. CHAPMAN: I agree with that idea com-
pletely, Dr. Bates. I would add, however, that a
$15,000 go is a completely different story from a
$500,000 go.
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